Tradenames starting with "T"

Patents whose numbers are in italics have been extended under 35 USC 156. All expiration dates include applicable Sec. 156 and pediatric (PED) extensions.


Takhzyro (Injection) (Subcutaneous) lanadelumab-flyo
NDA Applicant: Takeda Pharmaceuticals U.S.A., Inc.      BLA No.: 761090  Prod. No.: 001 Rx (300MG/2ML (150MG/ML))
ExclusivityExpirationExclusivity Description
Exclusivity Type: Orphan Drug ExclusivityAug 23, 2025Orphan Designation: Treatment of angioedema
Approved Labeled Indication: Prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older
Exclusivity Protected Indication: Prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older

Tecartus (For Injection) (Intravenous) Brexucabtagene Autoleucel
NDA Applicant: Kite Pharma Inc.      BLA No.: 125703  Prod. No.: 001 Rx (2×10^6 CAR-positive viable T cells per kg body weight)
ExclusivityExpirationExclusivity Description
Exclusivity Type: Orphan Drug ExclusivityJul 24, 2027Orphan Designation: Treatment of mantle cell lymphoma.
Approved Labeled Indication: TECARTUS_ is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)
Exclusivity Protected Indication: TECARTUS_ is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)
Exclusivity Type: Orphan Drug ExclusivityOct 1, 2028Orphan Designation: Treatment of acute lymphoblastic leukemia (ALL)
Approved Labeled Indication: Treatment of adult patients with relapsed or refractory B-cell precursor acute lymphomblastic leukemia (ALL)
Exclusivity Protected Indication: Treatment of adult patients with relapsed or refractory B-cell precursor acute lymphomblastic leukemia (ALL)

Tecentriq (Injection) (Intravenous) atezolizumab
Drug Classes: Antineoplastics:Monoclonal Antibody/Antibody-Drug Conjugate == human programmed death receptor-1 (PD-1)-blocking antibody
NDA Applicant: Genentech, Inc.      BLA No.: 761034  Prod. No.: 001 Rx (1200MG/20ML (60MG/ML)); 002 Rx (840MG/14ML (60MG/ML))
ExclusivityExpirationExclusivity Description
Exclusivity Type: Orphan Drug ExclusivityMar 18, 2026Orphan Designation: Treatment of small cell lung cancer (SCLC)
Approved Labeled Indication: TECENTRIQ_, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)
Exclusivity Protected Indication: TECENTRIQ_, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)
Exclusivity Type: Orphan Drug ExclusivityJul 30, 2027Orphan Designation: Treatment of Stage llb, llc, lll and IV melanoma
Approved Labeled Indication: indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma
Exclusivity Protected Indication: indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma

Tepezza (For Injection) (Intravenous) teprotumumab-trbw
NDA Applicant: Horizon Therapeutics Ireland DAC      BLA No.: 761143  Prod. No.: 001 Rx (500MG)
ExclusivityExpirationExclusivity Description
Exclusivity Type: Orphan Drug ExclusivityJan 21, 2027Orphan Designation: Treatment of active thyroid eye disease
Approved Labeled Indication: TEPEZZA is indicated for the treatment of Thyroid Eye Disease.
Exclusivity Protected Indication: For the treatment of active Thyroid Eye Disease

Thrombate Iii (For Injection) (Intravenous) Antithrombin III (Human)
Drug Classes: Blood Products and Modifiers:Blood Component Deficiency/ Replacement == recombinant antithrombin
NDA Applicant: Grifols Therapeutics LLC      BLA No.: 103196  Prod. No.: 001 Rx (500IU)
ExclusivityExpirationExclusivity Description
Exclusivity Type: Orphan Drug ExclusivityDec 30, 1998Orphan Designation: For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.

Thyrogen (For Injection) (Intramuscular) thyrotropin alfa
NDA Applicant: Genzyme Corporation      BLA No.: 020898  Prod. No.: 001 Rx (0.9MG)
ExclusivityExpirationExclusivity Description
Exclusivity Type: Orphan Drug ExclusivityNov 30, 2005Orphan Designation: As an adjunct in the diagnosis of thyroid cancer.
Approved Labeled Indication: As an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with thyroid cancer.
Exclusivity Type: Orphan Drug ExclusivityDec 14, 2014Orphan Designation: Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid
Approved Labeled Indication: For use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of metastatic thyroid cancer

Trasylol (Injection) (Intravenous) aprotinin
Drug Classes: antifibrinolytic
NDA Applicant: Bayer HealthCare Pharmaceuticals Inc.      BLA No.: 020304  Prod. No.: 001 Disc (1,000,000KIU/100ML (10,000KIU/ML)); 002 Disc (2,000,000KIU/200ML (10,000KIU/ML))
ExclusivityExpirationExclusivity Description
Exclusivity Type: Orphan Drug ExclusivityDec 29, 2000Orphan Designation: For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary c

Tretten (For Injection) (Intravenous) Coagulation Factor XIII A-Subunit (Recombinant)
Drug Classes: Blood Products and Modifiers:Blood Component Deficiency/ Replacement == human blood coagulation factor ==
NDA Applicant: Novo Nordisk Inc.      BLA No.: 125398  Prod. No.: 001 Rx (2000 - 3125IU)
ExclusivityExpirationExclusivity Description
Exclusivity Type: Orphan Drug ExclusivityDec 23, 2020Orphan Designation: Prophylaxis of bleeding associated with congential factor XIII deficiency
Approved Labeled Indication: Routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency.
Exclusivity Protected Indication: Routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency.

Trogarzo (Injection) (Intravenous) ibalizumab-uiyk
NDA Applicant: Theratechnologies Inc.      BLA No.: 761065  Prod. No.: 001 Rx (200MG/1.33ML (150MG/ML))
ExclusivityExpirationExclusivity Description
Exclusivity Type: Orphan Drug ExclusivityMar 6, 2025Orphan Designation: Treatment of HIV-1 infection in treatment experienced adult patients with documented multi-antiretroviral class resistance and evidence of HIV-1 replication despite ongoing antiretroviral therapy
Approved Labeled Indication: TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.
Exclusivity Protected Indication: TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.

Trumenba (Injection) (Intramuscular) Meningococcal Group B Vaccine
Drug Classes: Immunological Agents:Vaccines
NDA Applicant: Wyeth Pharmaceuticals LLC      BLA No.: 125549  Prod. No.: 001 Rx (0.5ML)
ExclusivityExpirationExclusivity Description
Exclusivity Type: Ref. Product ExclusivityOct 29, 2026 

Tysabri (Injection) (Intravenous) natalizumab
Drug Classes: Central Nervous System Agents:Multiple Sclerosis Agents == Immunological Agents:Immunological Agents, Other == integrin receptor antagonist
NDA Applicant: Biogen Inc.      BLA No.: 125104  Prod. No.: 001 Rx (300MG/15ML (20MG/ML))
PatentsExpirationPatented Use
Pat. No. 7157276 Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
Claim Types: Process
Pat. Sub. Date(s): None
Jun 21, 2024 
Pat. No. 7759117 Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
Claim Types: Process
Pat. Sub. Date(s): None
Jun 21, 2024 
Pat. No. 8124350 Methods and products for evaluating an immune response to a therapeutic protein
Claim Types: Diagnostic or surgical method
Pat. Sub. Date(s): None
Aug 2, 2027 
Pat. No. 8318416 Nutrient monitoring and feedback control for increased bioproduct production
Claim Types: Process
Pat. Sub. Date(s): None
Jan 20, 2031 
Pat. No. 8809049 Methods for producing mammalian cells
Claim Types: Process
Pat. Sub. Date(s): None
May 22, 2031 
Pat. No. 8871449 Methods and products for evaluating an immune response to a therapeutic protein
Claim Types: Diagnostic or surgical method
Pat. Sub. Date(s): None
Apr 12, 2026 
Pat. No. 9005926 Methods of preventing and removing trisulfide bonds
Claim Types: Process
Pat. Sub. Date(s): None
Oct 1, 2030 
Pat. No. 9096879 Method of supplementing culture media to prevent undesirable amino acid substitutions
Claim Types: Process
Pat. Sub. Date(s): None
Jan 7, 2031 
Pat. No. 9109015 Method of isolating biomacromolecules using low pH and divalent cations
Claim Types: Process
Pat. Sub. Date(s): None
Aug 13, 2031 
Pat. No. 9212379 Nutrient monitoring and feedback control for increased bioproduct production
Claim Types: Process
Pat. Sub. Date(s): None
Nov 28, 2030 
Pat. No. 9316641 Assay for JC virus antibodies
Claim Types: Diagnostic or surgical method
Pat. Sub. Date(s): None
Jan 9, 2032 
Pat. No. 9493567 Methods of treating inflammatory and autoimmune diseases with natalizumab
Claim Types: Method of use
Pat. Sub. Date(s): None
Mar 5, 2027 
Pat. No. 9562252 Methods of preventing and removing trisulfide bonds
Claim Types: Process
Pat. Sub. Date(s): None
May 11, 2033 
Pat. No. 9696307 Methods for the detection of JC polyoma virus
Claim Types: Diagnostic or surgical method
Pat. Sub. Date(s): None
Feb 5, 2030 
Pat. No. 9709575 Methods and products for evaluating an immune response to a therapeutic protein
Claim Types: Diagnostic or surgical method
Pat. Sub. Date(s): None
Apr 4, 2026 
Pat. No. 9790533 Methods of preventing and removing trisulfide bonds
Claim Types: Cell culture
Pat. Sub. Date(s): None
May 11, 2032 
Pat. No. 9994968 Electrochemical etching apparatus
Claim Types: Process
Pat. Sub. Date(s): None
Aug 19, 2034 
Pat. No. 10023831 Gas delivery devices and associated systems and methods
Claim Types: Device
Pat. Sub. Date(s): None
Mar 17, 2035 
Pat. No. 10119976 Method of assessing risk of PML
Claim Types: Diagnostic or surgical method; Method of use
Pat. Sub. Date(s): None
May 27, 2034 
Pat. No. 10233245 Methods of treating inflammatory and autoimmune diseases with natalizumab
Claim Types: Method of use
Pat. Sub. Date(s): None
Feb 28, 2027 
Pat. No. 10308706 Methods of preventing and removing trisulfide bonds
Claim Types: Process
Pat. Sub. Date(s): None
Feb 5, 2032 
Pat. No. 10444234 Assay for JC virus antibodies
Claim Types: Diagnostic or surgical method; Device
Pat. Sub. Date(s): None
Jan 11, 2031 
Pat. No. 10590454 Methods of preventing and removing trisulfide bonds
Claim Types: Process
Pat. Sub. Date(s): None
May 11, 2032 
Pat. No. 10676772 Control of protein glycosylation by culture medium supplementation and cell culture process parameters
Claim Types: Process
Pat. Sub. Date(s): None
Aug 19, 2034 
Pat. No. 10677803 Method of assessing risk of PML
Claim Types: Method of use
Pat. Sub. Date(s): None
May 27, 2034 
Pat. No. 10705095 Methods and products for evaluating an immune response to a therapeutic protein
Claim Types: Diagnostic or surgical method
Pat. Sub. Date(s): None
Apr 4, 2026 
Pat. No. 10844416 Manganese supplementation for control of glycosylation in mammalian cell culture process
Claim Types: Process
Pat. Sub. Date(s): None
Jan 6, 2036 
Pat. No. 11124760 Methods for overcoming glutamine deprivation during mammalian cell culture
Claim Types: Process
Pat. Sub. Date(s): None
Aug 27, 2035 
Pat. No. 11268119 Copper supplementation for control of glycosylation in mammalian cell culture process
Claim Types: Process
Pat. Sub. Date(s): None
Feb 21, 2036 
Pat. No. 11280794 Method of assessing risk of PML
Claim Types: Method of use
Pat. Sub. Date(s): None
May 27, 2034 
Pat. No. 11287423 Assay for JC virus antibodies
Claim Types: Formulation; Process
Pat. Sub. Date(s): None
Jan 11, 2031 
Pat. No. 11292845 Methods of treating inflammatory and autoimmune diseases with natalizumab
Claim Types: Method of use
Pat. Sub. Date(s): None
Feb 28, 2027 



Last edited: 15 November 2022
© 2001-2022 Bruce A. Pokras, All rights reserved worldwide